Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-interventional, Observational Cohort Study of Chronic Lymphocytic Leukaemia Patients Treated With Acalabrutinib in the First-line Setting Through the UK Early Access Programme: Early Access Programme Outcomes In aCalabrutinib (EPIC).

NCT05557695 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05557695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05557695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-interventional, Observational Cohort Study of Chronic Lymphocytic Leukaemia Patients Treated With Acalabrutinib in the First-line Setting Through the UK Early Access Programme: Early Access Programme Outcomes In aCalabrutinib (EPIC).
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
October 17, 2022
Completion date
April 1, 2027
Enrollment
287 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, cll